Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Given Average Recommendation of “Hold” by Analysts

Shares of Alpine Immune Sciences, Inc. (NASDAQ:ALPN) have been assigned a consensus recommendation of “Hold” from the eleven brokerages that are covering the firm, Marketbeat Ratings reports. Eight research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $50.33.

A number of brokerages have recently issued reports on ALPN. Wedbush downgraded shares of Alpine Immune Sciences from an “outperform” rating to a “neutral” rating in a report on Thursday, April 11th. Wolfe Research reissued a “peer perform” rating on shares of Alpine Immune Sciences in a report on Thursday, April 11th. HC Wainwright downgraded shares of Alpine Immune Sciences from a “buy” rating to a “neutral” rating in a report on Thursday, April 11th. Leerink Partnrs downgraded shares of Alpine Immune Sciences from an “outperform” rating to a “market perform” rating in a report on Thursday, April 11th. Finally, Royal Bank of Canada reissued a “sector perform” rating and issued a $65.00 price objective (up previously from $41.00) on shares of Alpine Immune Sciences in a report on Thursday, April 11th.

Alpine Immune Sciences Stock Up 0.2 %

Shares of NASDAQ ALPN opened at $64.55 on Friday. The firm’s 50-day moving average price is $40.09 and its 200-day moving average price is $24.89. The company has a market cap of $4.23 billion, a PE ratio of -100.86 and a beta of 1.14. Alpine Immune Sciences has a 52-week low of $6.71 and a 52-week high of $64.57.

Alpine Immune Sciences (NASDAQ:ALPN) last announced its quarterly earnings results on Monday, March 18th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.47. The firm had revenue of $30.85 million for the quarter, compared to the consensus estimate of $6.90 million. Alpine Immune Sciences had a negative net margin of 54.66% and a negative return on equity of 15.54%. As a group, equities research analysts anticipate that Alpine Immune Sciences will post -1.74 EPS for the current fiscal year.

Institutional Investors Weigh In On Alpine Immune Sciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. raised its stake in Alpine Immune Sciences by 429.8% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,723 shares of the biotechnology company’s stock worth $128,000 after acquiring an additional 5,454 shares during the period. Walleye Capital LLC raised its position in shares of Alpine Immune Sciences by 13.1% during the third quarter. Walleye Capital LLC now owns 186,273 shares of the biotechnology company’s stock valued at $2,133,000 after buying an additional 21,600 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Alpine Immune Sciences by 5.1% during the third quarter. Vanguard Group Inc. now owns 1,474,879 shares of the biotechnology company’s stock valued at $16,887,000 after buying an additional 70,912 shares during the last quarter. Nan Fung Group Holdings Ltd bought a new stake in shares of Alpine Immune Sciences during the third quarter valued at approximately $2,087,000. Finally, Schonfeld Strategic Advisors LLC raised its position in shares of Alpine Immune Sciences by 604.9% during the third quarter. Schonfeld Strategic Advisors LLC now owns 90,937 shares of the biotechnology company’s stock valued at $1,041,000 after buying an additional 78,037 shares during the last quarter. Institutional investors own 75.17% of the company’s stock.

Alpine Immune Sciences Company Profile

Alpine Immune Sciences, Inc operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus.